TimesSquare Capital Management LLC Acquires New Holdings in Mineralys Therapeutics, Inc. $MLYS

Posted by Francis Steltz on May 20th, 2026

TimesSquare Capital Management LLC acquired a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 380,100 shares of the company’s stock, valued at approximately $13,794,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Navalign LLC acquired a new position in shares of Mineralys Therapeutics in the fourth quarter valued at approximately $33,000. Smartleaf Asset Management LLC boosted its holdings in shares of Mineralys Therapeutics by 198.2% in the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after buying an additional 676 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Mineralys Therapeutics by 14,091.3% in the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after buying an additional 3,241 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Mineralys Therapeutics by 50.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,846 shares of the company’s stock valued at $140,000 after buying an additional 1,283 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Mineralys Therapeutics by 29.8% in the second quarter. The Manufacturers Life Insurance Company now owns 14,775 shares of the company’s stock valued at $200,000 after buying an additional 3,390 shares during the period. Institutional investors and hedge funds own 84.46% of the company’s stock.

Insider Buying and Selling at Mineralys Therapeutics

In related news, Director Daphne Karydas sold 3,000 shares of the stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $25.00, for a total transaction of $75,000.00. Following the completion of the transaction, the director owned 6,200 shares in the company, valued at approximately $155,000. This represents a 32.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ra Capital Management, L.P. bought 310,700 shares of Mineralys Therapeutics stock in a transaction that occurred on Friday, March 27th. The shares were acquired at an average price of $23.67 per share, with a total value of $7,354,269.00. Following the acquisition, the director directly owned 5,767,221 shares of the company’s stock, valued at $136,510,121.07. The trade was a 5.69% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have sold 162,291 shares of company stock worth $4,353,683. Company insiders own 18.94% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a report on Friday, March 13th. HC Wainwright set a $56.00 price target on shares of Mineralys Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Tuesday, April 21st. Wall Street Zen cut shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, TD Cowen assumed coverage on shares of Mineralys Therapeutics in a report on Monday, April 27th. They issued a “buy” rating for the company. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $49.33.

Get Our Latest Analysis on Mineralys Therapeutics

Mineralys Therapeutics Trading Down 1.4%

Shares of MLYS opened at $26.03 on Wednesday. Mineralys Therapeutics, Inc. has a 12 month low of $12.59 and a 12 month high of $47.65. The firm has a fifty day simple moving average of $27.05 and a 200 day simple moving average of $32.37. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -12.70 and a beta of 0.49.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.04. As a group, research analysts predict that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Mineralys Therapeutics Profile

(Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.